Summary of experimental treatments
| Agonist Dose | Agonist Pretreatment | Antagonist Dose | Antagonist Pretreatment | Antagonist AD50 or ED50 | Potency Relative to Training Condition |
|---|---|---|---|---|---|
| mg/kg | h | mg/kg | hr | ± S.E.M. | |
| SAL | 4.0 | NTX 3.0–100 | 0.25 | >100 | |
| MOR, 10 | 4.0 | NTX 0.003–3.0 | 0.25 | 0.05 ± 0.02 | |
| MOR, 10 | 0.25–8.0 | NTX 0.3 | 0.25 | ||
| MOR, 10 | 3.5 | NTX 0.3 | 0.25–2.0 | ||
| MOR, 10 | 4.0 | NTX 0.001–1.0 | 4.25 | 0.11 ± 0.04 | |
| NTX 0.3 | 0.25 | ||||
| MOR, 1.0 | 4.0 | NTX 0.3–10 | 0.25 | 2.1 ± 0.62 | 0.024a,b |
| MOR, 3.0 | 4.0 | NTX 0.3 | 0.25 | ||
| MOR, 10 | 0.5 | NTX 1.0–100 | 0.25 | >100 | |
| MOR, 10 | 1.0 | NTX 1.0–30 | 0.25 | 3.66 ± 1.02 | 0.014a,b |
| SAL | 4.0 | NX 30 | 0.25 | ||
| MOR, 10 | 4.0 | NX 0.03–30 | 0.25 | 0.35 ± 0.09 | 0.14a,b |
| Pump MOR 20, 280 | 14 days | NTX 0.001–1.0 (days 7–13) | 0.25 | 0.04 ± 0.02 | 1.251-a |
| Pump MOR 40, 340 | 7 days | NTX 0.001–0.01 (days 5–6) | |||
| MOR, 10 | 4.0 | NTX 0.003–3.0 | 0.25 | 0.03 ± 0.01 | 1.671-a |
| Pump MOR 40, 340 | 7 days | NTX 0.001–0.01 (days 5–6) | 0.25 | 0.005 ± 0.0002 | 10a,b |
↵1-a Significantly different from SAL-pretreated controlp ≤ 0.05.
1-b A significant potency difference relative to training dose or time (p ≤ 0.05).